(Q37961728)

26 August 2017

Small-molecule chromatin-modifying agents: therapeutic applications (English)

1 reference

26 August 2017

Antonello Mai

1

0 references

publication date

1 April 2010

1 reference

26 August 2017

1 reference

26 August 2017

2

1 reference

26 August 2017

2

1 reference

26 August 2017

307-324

1 reference

Epigenetics: a landscape takes shape

26 August 2017

1 reference

Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead

21 January 2018

1 reference

The therapeutic uses of chromatin-modifying agents

21 January 2018

1 reference

Histone acetyltransferase inhibitors and preclinical studies

21 January 2018

1 reference

Non-cancer uses of histone deacetylase inhibitors: effects on infectious diseases and beta-hemoglobinopathies

21 January 2018

1 reference

The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors

21 January 2018

1 reference

Cancer treatment of the future: inhibitors of histone methyltransferases

21 January 2018

1 reference

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

21 January 2018

1 reference

Histone acetyl transferases as emerging drug targets.

21 January 2018

1 reference

Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise

21 January 2018

1 reference

Chromatin modifications and their function

21 January 2018

1 reference

Acetylation and chromosomal functions.

21 January 2018

1 reference

Histone acetylation in chromatin structure and transcription

21 January 2018

1 reference

Enhanced histone acetylation and transcription: a dynamic perspective

21 January 2018

1 reference

Functions of site-specific histone acetylation and deacetylation

21 January 2018

1 reference

Multivalent engagement of chromatin modifications by linked binding modules

21 January 2018

1 reference

Deacetylase enzymes: biological functions and the use of small-molecule inhibitors

21 January 2018

1 reference

Histone deacetylation in epigenetics: an attractive target for anticancer therapy

21 January 2018

1 reference

Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression

21 January 2018

1 reference

Class II histone deacetylases: versatile regulators

21 January 2018

1 reference

Class IIa histone deacetylases: regulating the regulators

21 January 2018

1 reference

Histone deacetylase inhibitors: Potential in cancer therapy

21 January 2018

1 reference

HDAC family: What are the cancer relevant targets?

21 January 2018

1 reference

MEF2: a calcium-dependent regulator of cell division, differentiation and death

21 January 2018

1 reference

HDAC6 is a microtubule-associated deacetylase

21 January 2018

1 reference

The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

21 January 2018

1 reference

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

Histone deacetylases and cancer

21 January 2018

1 reference

Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis

21 January 2018

1 reference

Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins

21 January 2018

1 reference

PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia

21 January 2018

1 reference

The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia

21 January 2018

1 reference

Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins

21 January 2018

1 reference

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

21 January 2018

1 reference

Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.

21 January 2018

1 reference

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

21 January 2018

1 reference

Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases

21 January 2018

1 reference

Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor

21 January 2018

1 reference

Crystal structure of a bacterial class 2 histone deacetylase homologue

21 January 2018

1 reference

Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain

21 January 2018

1 reference

Residues in the 11 A channel of histone deacetylase 1 promote catalytic activity: implications for designing isoform-selective histone deacetylase inhibitors

21 January 2018

1 reference

On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors

21 January 2018

1 reference

Sodium butyrate induces human colon carcinoma HT-29 cell apoptosis through a mitochondrial pathway

21 January 2018

1 reference

Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo

21 January 2018

1 reference

Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer

21 January 2018

1 reference

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

21 January 2018

1 reference

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

21 January 2018

1 reference

Clinical studies of histone deacetylase inhibitors.

21 January 2018

1 reference

Epigenetic modifiers: basic understanding and clinical development.

21 January 2018

1 reference

N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).

21 January 2018

1 reference

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

21 January 2018

1 reference

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

21 January 2018

1 reference

Isoform-selective histone deacetylase inhibitors.

21 January 2018

1 reference

Romidepsin for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives

21 January 2018

1 reference

The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells

21 January 2018

1 reference

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models

21 January 2018

1 reference

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors

21 January 2018

1 reference

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

21 January 2018

1 reference

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

21 January 2018

1 reference

New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations

21 January 2018

1 reference

Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides

21 January 2018

1 reference

Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes

21 January 2018

1 reference

Specific activity of class II histone deacetylases in human breast cancer cells

21 January 2018

1 reference

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

21 January 2018

1 reference

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

21 January 2018

1 reference

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

21 January 2018

1 reference

Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis

21 January 2018

1 reference

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

21 January 2018

1 reference

Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

21 January 2018

1 reference

Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer

21 January 2018

1 reference

HDAC inhibitors: clinical update and mechanism-based potential.

21 January 2018

1 reference

Enhancing the apoptotic and therapeutic effects of HDAC inhibitors

21 January 2018

1 reference

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect

21 January 2018

1 reference

Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase

21 January 2018

1 reference

Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents.

21 January 2018

1 reference

Potent antimalarial activity of histone deacetylase inhibitor analogues.

21 January 2018

1 reference

Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors

21 January 2018

1 reference

A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum

21 January 2018

1 reference

Histone Deacetylase Inhibitors

21 January 2018

1 reference

Candidaemia in Europe: epidemiology and resistance

21 January 2018

1 reference

Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation

21 January 2018

1 reference

Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans

21 January 2018

1 reference

Histone deacetylase inhibitors may reduce pathogenicity and virulence in Candida albicans

21 January 2018

1 reference

Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.

21 January 2018

1 reference

Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies

21 January 2018

1 reference

The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention

21 January 2018

1 reference

NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation

21 January 2018

1 reference

c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter

21 January 2018

1 reference

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

21 January 2018

1 reference

"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence

21 January 2018

1 reference

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report

21 January 2018

1 reference

Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila

21 January 2018

1 reference

Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease.

21 January 2018

1 reference

Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity.

21 January 2018

1 reference

The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases.

21 January 2018

1 reference

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

21 January 2018

1 reference

The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice

21 January 2018

1 reference

Histone deacetylase inhibitors that target tubulin

21 January 2018

1 reference

HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS

21 January 2018

1 reference

Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.

21 January 2018

1 reference

Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity

21 January 2018

1 reference

Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity.

21 January 2018

1 reference

Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.

21 January 2018

1 reference

Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases

21 January 2018

1 reference

HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model

21 January 2018

1 reference

Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing

21 January 2018

1 reference

Sirtuins in mammals: insights into their biological function

21 January 2018

1 reference

Recent progress in the biology and physiology of sirtuins

21 January 2018

1 reference

The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase

21 January 2018

1 reference

SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis

21 January 2018

1 reference

The Sir2 family of protein deacetylases

21 January 2018

1 reference

Acetylation inactivates the transcriptional repressor BCL6.

21 January 2018

1 reference

hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase

21 January 2018

1 reference

Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.

21 January 2018

1 reference

Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation

21 January 2018

1 reference

Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase

21 January 2018

1 reference

Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening

21 January 2018

1 reference

Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors

21 January 2018

1 reference

Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect.

21 January 2018

1 reference

Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1.

21 January 2018

1 reference

Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage

21 January 2018

1 reference

Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes

21 January 2018

1 reference

Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

21 January 2018

1 reference

Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease

21 January 2018

1 reference

Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective

21 January 2018

1 reference

Opposing activities protect against age-onset proteotoxicity

21 January 2018

1 reference

Mammalian Sir2-related protein (SIRT) 2-mediated modulation of resistance to axonal degeneration in slow Wallerian degeneration mice: a crucial role of tubulin deacetylation

21 January 2018

1 reference

A century of Alzheimer's disease

21 January 2018

1 reference

Therapeutic role of sirtuins in neurodegenerative disease.

21 January 2018

1 reference

SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis

21 January 2018

1 reference

Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides.

21 January 2018

1 reference

Paths of convergence: sirtuins in aging and neurodegeneration

21 January 2018

1 reference

SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling

21 January 2018

1 reference

SIRT1 negatively regulates HDAC1-dependent transcriptional repression by the RBP1 family of proteins

21 January 2018

1 reference

Trans-regulation of histone deacetylase activities through acetylation

21 January 2018

1 reference

Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

21 January 2018

1 reference

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

21 January 2018

1 reference

Synthesis and Biological Properties of Novel, Uracil-Containing Histone Deacetylase Inhibitors

21 January 2018

1 reference

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/EPI.10.7

1 reference

release_itrdk7u6x5ffjhekgh2uy4cw4u

26 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/itrdk7u6x5ffjhekgh2uy4cw4u

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

22121876

1 reference

PubMed ID

22121876